AUROBINDO PHARMA LTD vs MANKIND PHARMA LIMITED

A side-by-side comparison of AUROBINDO PHARMA LTD (AUROPHARMA) and MANKIND PHARMA LIMITED (MANKIND) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, AUROBINDO PHARMA LTD leads AUROPHARMA vs MANKIND on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation40
  • Profitability04
  • Growth11
  • Size & financial health31
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

AUROPHARMA takes 4/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

27.85
P/E ratio
51.07
2.39
P/B ratio
6.30
0.24%
Dividend yield
0.04%
₹60.34
EPS
₹46.34

Profitability

MANKIND takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

10.10%
Return on equity
13.10%
13.00%
Return on capital
14.00%
20.00%
EBITDA margin
25.00%
10.41%
Net margin
13.57%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.63%
Revenue CAGR (3Y)
17.73%
22.02%
Profit CAGR (3Y)
13.94%

Size & financial health

AUROPHARMA takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹96,853 Cr
Market cap
₹97,768 Cr
₹33,653 Cr
Revenue
₹14,278 Cr
₹3,503 Cr
Net profit
₹1,938 Cr
0.19
Debt / equity
0.34
AUROBINDO PHARMA LTD
  • ["Stock is trading at 2.52 times its book value", "The company has delivered a poor sales growth of 6.32% over past five years.", "Company has a low return on equity of 10.8% over last 3 years.", "Company might be capitalizing the interest cost"]
MANKIND PHARMA LIMITED
  • + ["Company has reduced debt."]
  • ["Promoter holding has decreased over last 3 years: -3.87%"]
AUROBINDO PHARMA LTD full analysis MANKIND PHARMA LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.